Obesity dominates as future blockbusters are identified

In its Drugs to Watch 2026 report, Clarivate highlights eleven therapies in development that are “poised to reshape treatment paradigms, enhance patient outcomes and, in most cases, achieve blockbuster status”.

The most promising therapies are expected within the rapidly expanding obesity and diabetes segment — and both originate from U.S.-based Eli Lilly, which last year became the first pharmaceutical company to reach a staggering one trillion dollars in market value.